Rosiglitazone, which is used to treat type 2 diabetes, may increase the risk of heart problems.
A new study shows that patients who initiated treatment with blood pressure or cholesterol medications were more likely to reduce activity and gain weight.
SGLT2 inhibitor therapy provided protective effects from cardiovascular (CV) events in patients with type 2 diabetes with or without established CV disease.
Ticagrelor (Brilinta, AstraZeneca) reduced the risk of stroke and death when taken with aspirin compared with aspirin alone.
The FDA has approved semaglutide (Ozempic, Novo Nordisk) for the reduction of major adverse cardiovascular (CV) events in patients with type 2 diabetes and established CV disease.
Individuals with a history of heart disease may be at an increased risk of developing kidney failure.
Are the benefits of lowering systolic blood pressure to less than 130 mm Hg the same for those aged 80 years and older as they are for younger patients?
AstraZeneca’s supplemental New Drug Application for dapagliflozin (Farxiga) has been granted Priority Review by the FDA.
The approvals were granted to generic apixaban applications from Micro Labs Limited and Mylan Pharmaceuticals Inc.
Invasive methods did not perform better than drug treatment in patients with stable ischemic heart disease